Construction of expression vector 1
An overlap cloning was performed to make the entry clone for anti-HER2(scFv). Genes encoding VH 2 and VL of trastuzumab were synthesized by Bioneer (Daejeon, Korea). The VH and VL regions of 3 trastuzumab were amplified using primers: 5'-4 GGCTTCGAAAACCTGTATTTTCAGGGCGAAGTACAATTGGTTGAAAGCGGGGGTGG and 5'-5 CCCGAGCCACCGCCACCTGAGCCACCGCCACCGGAGCTTACAGTTACCAGA GTACCCTGG for 6 VH, 5'-7 GCTCAGGTGGCGGTGGCTCGGGTGGCGGTGGCTCAGATATTCAAATGACACAAAGCCCCTCTA 8 G and 5'-9 GCCTTTGTACAAGAAAGCTGGGTTTAGCATTTAATTTCAACCTTCGTTCCCTGACCAAATG for 10 VL. Primers were designed for PCR products to have homologous sequence at both ends. attL1 and attL2 11 sites at each end of VH and VL were added, and scFv was formed via the linker (G4S)4 between VH and VL. 12
In additional, the tobacco etch virus protease recognition site (TEVrs) at the N-terminus of HER2(scFv) and 13
Cys residue at the C-terminus were inserted for tag removal and conjugation reaction, respectively. After 14 overlap cloning with amplified donor vector (pDONR207), entry clone was formed. MBP-HER2(scFv) 15 expression vector was created by multisite gateway cloning (LR reaction) with the destination vector 16 (pDEST-HMGWA) and entry clone. In case of PE24, the PE24 sequence 27) was codon-optimized for E. coli 17 expression and synthesized. The gene was amplified by PCR with the primers designed to include attB1 and 18 attB2 sites at both ends of PE24: 5'-19 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAGAATCTGTATTTCCAAGG and 5'-20 GGGGACCACTTTGTACAAGAAAGCTGGGTTTACTTCAGA TCCTCACG. Then, the PCR product 21 was inserted to the vector containing attP1 and attP2 sites by multisite gateway cloning (BP reaction). With 22 the newly formed entry clone (pENTR-PE24) and destination vector (pDest-His8), multi-LR reaction was 23 performed. As a result, the expression vector for His8-PE24 was created. Correct constructs were confirmed 24 by sequencing analysis (Macrogen, Daejeon, Korea) 25
Expression and solubility analysis of recombinant fusion protein in E .coli, BL21 1 For the transformation of expression plasmid into E. coli, BL21 strain was created by the heat shock method. 2
Single colony was inoculated in the Luria-Bertani (LB) medium containing 50 µg/mL overnight at 37°C. 3
The cultured cells were diluted into 4 mL of fresh LB medium at a ratio of 1:50, and the cells were grown at 4 37°C. When the value of OD600 reached 0.6-0.7, 0.5 mM IPTG was added and cell was inducted at 37°C for 5 3 h or 18°C for overnight. Cells were harvested and resuspended with sonication buffer containing 20 mM 6
Tris, pH 8.0, 1 mM EDTA, and 20% glycerol (v/v). Resuspended cells were sonicated by ultrasonic cell 7 disruptor. To obtain soluble fraction and pellet fraction, sonicated cell was centrifuge at 23,000 g for 10 min. 8 9
Purification of HER2(scFv)-Cys and PE24 10
For 500 mL of culture, one colony was inoculated in 5 mL of LB with 50 µg/mL of ampicillin and 11 grown at 37°C overnight. The cultured cell was diluted with 500 mL of LB containing ampicillin at a 1:100 12 ratio and grown at 37°C until OD600 = 0.6. At this stage, 0.5 mM IPTG was added to the culture and 13 incubated at 18°C overnight to induce protein expression. Cultured and induced cells were harvested by 14 centrifugation at 3,800 g for 20 min at 4°C. After centrifugation, some medium was removed and pellets 15 were resuspended with the remaining medium. Resuspended pellets were collected to 50 mL falcon tube and 16 centrifuged at 3,800 g for 30 min at 4°C. Cell pellets were stored at -20°C until used. For the purification of 17 fusion protein, MBP-HER2(scFv) or His8-PE24, cell pellets were resuspended with 100 mL of buffer A 18 containing 20 mM Tris, pH 8.0, 500 mM NaCl and 5% glycerol(v/v). Suspended pellets were sonicated and 19 homogenized by ultrasonic cell disruptor JY99-IIDN. The cell lysate was centrifuged at 23,000 g for 20 min 20 at 4°C. After centrifugation, the supernatant was filtered with 0.45 µm filter and was applied to 10 mL 21 HiTrap Ni HP that was already equilibrated with buffer A. After applying the cell lysate, 30 mM imidazole 22 was allowed to flow in the column for 5 CV to wash off unbounded proteins. When 100 mM imidazole had 23 flowed in the column for 3-4 CV, MBP-HER2 fusion protein was eluted and collected. In case of his8-24 protein:TEV = 5:1, w/w) or His8 tag of His-PE24 (fusion protein:TEV = 20:1, w/w). Tag cleavage by TEV 1 protease was performed at 18°C overnight. The TEV-treated mixture was dialyzed against buffer A and 2 applied to 10 mL HiTrap Ni HP that was equilibrated with the same buffer. The tag-free HER2(scFv) or 3 PE24 did not bind to the column and was eluted from flow through (FT). The His-MBP tag or His8 tag and 4
His7-TEV protease were eluted at 500 mM imidazole. The purified HER2(scFv) or PE24 was concentrated 5 by Amicon Ultra from Merck Millipore by centrifuging at 3,800 g and dialyzed against PBS at pH 7.4. 6 7 Crosslinking of HER2(scFv) and PE24 8
In this process, 12.5 µL of 20 mM sulfo-LC-SPDP was added to 1 mg of PE24 in PBS (pH 7.4) and 9 1 mM EDTA. The reaction mixture was incubated at room temperature for 40 min and dialyzed against PBS 10 (pH 7.4) and 5 mM EDTA to remove excess unreacted SPDP reagent. Then, 1 mg/mL of HER2(scFv)-Cys 11 was reduced by 10 mM TCEP to form monomer and was incubated at room temperature for 40 min. 12 Unreacted TCEP was removed by dialysis against PBS (pH 7.4) and 5 mM EDTA. SPDP-modified PE24 13 was added to reduce HER2(scFv) at a 5:1 molar ratio (PE24:HER2(scFv)) and incubated at room 14 temperature for 30 min or at 4°C overnight. 15 well. After culture for 24 h, the HER2(scFv)-PE24 conjugate was treated to seeded cell at various 1 concentration (0.002, 0.02, 0.2, 2, 20, 200 nM) in triplicate. At 72 h after incubation with the conjugate, the 2 media was removed, and cells were washed with PBS. Then, 0.5 mL of the MTT solution (0.04 mg/mL in 3 serum-free medium) was added into the wells, and the plate was incubated for 2 hr. Then, the MTT solution 4 was removed, and 0.5 mL of DMSO was added. The plate was incubated for 1 h and absorbance at 595 nm 5 was measured. Cell viability was calculated using the following equation and Microsoft Excel : 6 V = top -(top -bottom)/(1 + (IC50 / conc.) HC ) 7
Where V means cell viability, top is the highest value of cell viability, bottom is the lowest value of cell 8 viability, conc. is the treated conjugate concentration and HC is the Hill coefficient of inhibition. 9 Tables  1   Supplementary Table 1 
